Terminal phase half-life of fenelidone

Finerenone (Finerenone) is a selective nonsteroidal mineralocorticoid receptor antagonist that has received regulatory approval for cardiorenal protection in patients with chronic kidney disease associated with type 2 diabetes. It is rapidly and completely absorbed and undergoes first-pass metabolism in the intestinal wall and liver, with a bioavailability of 43.5%. It blocks the action of aldosterone in the body by binding to aldosterone receptors, thereby reducing salt and water retention, lowering blood pressure, improving heart failure symptoms, and protecting kidney function.

The terminal half-life of fenelinone is approximately2 to 3 hours. Half-life refers to the time it takes for a drug to be metabolized and excreted in the body. The shorter the half-life, the faster the drug is eliminated. This means that the concentration of fenelinone in the body decreases rapidly, requiring frequent dosing to maintain efficacy. However, the systemic blood clearance rate of fenelinone is approximately 25L/h, which represents the amount of drug cleared from the blood per unit time. A higher clearance rate means that fenelinone is metabolized and excreted faster in the body, helping to maintain a stable blood concentration.

Despite the short terminal half-life of fenelinone, it can still exert its therapeutic effects effectively due to its selectivity and specific drug metabolism pathways. The metabolic pathway of drugs is mainly carried out through the enzyme system of the liver, in which CYP450 enzymes are the main enzymes involved. The metabolites of fenelidone are mainly excreted through the kidneys.

In summary, fenelidone is a selective aldosterone receptor antagonist used to treat heart failure and chronic kidney disease. Although its terminal half-life is short, its systemic blood clearance is high, helping to maintain stable blood concentrations of the drug. Knowledge of the pharmacokinetic parameters of the drug is important for proper use and monitoring of the efficacy of fenelidone.